Delivers 2x increase in AAV titers compared to market alternates. Reduce plasmid input, halve the bioreactors, and significantly lower cost per dose. HORSHAM, Pa., Aug. 12, 2025 /PRNewswire/ -- In a ...
As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially ...
Adeno-associated viruses (AAV) have emerged as pivotal delivery vehicles for gene therapy due to their overall safety (less immunogenic), efficiency (broad tropism), and long-term gene expression.
BEDFORD, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, offers The Full Solution™ suite of services, which includes end-to-end development and manufacturing capabilities for ...
Viral vectors are key delivery tools for advanced therapies, enabling gene transfer to treat inherited disorders, cancer and other serious diseases. Despite rapid clinical progress, manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results